Pharma Mar, S.A. (BME: PHM)

Market Cap	1.31B
Revenue (ttm)	167.00M
Net Income (ttm)	622.00K
Shares Out	17.54M
EPS (ttm)	0.03
PE Ratio	n/a
Forward PE	37.53
Dividend	0.65 (0.87%)
Ex-Dividend Date	Jun 12, 2024

Volume	20,580
Open	74.35
Previous Close	74.55
Day's Range	72.90 - 74.80
52-Week Range	26.16 - 83.70
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 509
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2023, Pharma Mar's revenue was 158.15 million, a decrease of -19.45% compared to the previous year's 196.34 million. Earnings were 1.14 million, a decrease of -97.70%.